B

Bavarian Nordic A/S
CSE:BAVA

Watchlist Manager
Bavarian Nordic A/S
CSE:BAVA
Watchlist
Price: 152.95 DKK 0.26% Market Closed
Market Cap: 12.1B DKK

Relative Value

The Relative Value of one BAVA stock under the Base Case scenario is 203.21 DKK. Compared to the current market price of 152.95 DKK, Bavarian Nordic A/S is Undervalued by 25%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BAVA Relative Value
Base Case
203.21 DKK
Undervaluation 25%
Relative Value
Price
B
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
85
vs Industry
76
Median 3Y
2.7
Median 5Y
5.7
Industry
7
Forward
1.8
vs History
49
vs Industry
9
Median 3Y
12.2
Median 5Y
12.2
Industry
21.8
Forward
8.8
vs History
63
vs Industry
14
Median 3Y
7.5
Median 5Y
8.2
Industry
19.3
vs History
11
vs Industry
3
Median 3Y
-8.1
Median 5Y
-8.7
Industry
22.7
vs History
98
vs Industry
58
Median 3Y
1.4
Median 5Y
1.9
Industry
2.4
vs History
90
vs Industry
68
Median 3Y
2.5
Median 5Y
5.4
Industry
7.3
Forward
1.5
vs History
79
vs Industry
62
Median 3Y
4.7
Median 5Y
12.4
Industry
8.8
vs History
61
vs Industry
13
Median 3Y
6.6
Median 5Y
8.4
Industry
4
Forward
4.4
vs History
42
vs Industry
10
Median 3Y
8.5
Median 5Y
8.5
Industry
3.7
Forward
6.2
vs History
63
vs Industry
15
Median 3Y
6.4
Median 5Y
7.1
Industry
4.5
vs History
15
vs Industry
3
Median 3Y
-7.8
Median 5Y
-10.4
Industry
3.2
vs History
96
vs Industry
57
Median 3Y
1.2
Median 5Y
1.5
Industry
4.5

Multiples Across Competitors

BAVA Competitors Multiples
Bavarian Nordic A/S Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Bavarian Nordic A/S
CSE:BAVA
12B DKK 2.1 12.2 6.2 10.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 908 997.7 -165 917.3 -201 476.5 -199 177.4
US
Abbvie Inc
NYSE:ABBV
328.7B USD 5.8 77.6 15.4 23.2
US
Amgen Inc
NASDAQ:AMGN
150.8B USD 4.5 36.9 15.2 26.9
US
Gilead Sciences Inc
NASDAQ:GILD
129.4B USD 4.5 269.7 10.6 13.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.1B USD 11.4 -235.5 25.8 27
US
Epizyme Inc
F:EPE
94.1B EUR 2 018.1 -515 -560.8 -545.8
AU
CSL Ltd
ASX:CSL
117.1B AUD 4.9 27.3 16.9 21.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
65.7B USD 4.6 14.9 9.4 10.4
US
Seagen Inc
F:SGT
39.3B EUR 19.4 -59.6 -64.2 -57.9
NL
argenx SE
XBRU:ARGX
32.4B EUR 16.8 44.2 -2 501.1 -1 676.9
P/S Multiple
Revenue Growth P/S to Growth
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average P/S: 3 173 735.5
2.1
6%
0.4
FR
Pharnext SCA
OTC:PNEXF
34 908 997.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.8
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.5
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.4
10%
1.1
US
E
Epizyme Inc
F:EPE
2 018.1
N/A N/A
AU
CSL Ltd
ASX:CSL
4.9
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.6
7%
0.7
US
S
Seagen Inc
F:SGT
19.4
30%
0.6
NL
argenx SE
XBRU:ARGX
16.8
37%
0.5
P/E Multiple
Earnings Growth PEG
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average P/E: 69
12.2
0%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 917.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
77.6
87%
0.9
US
Amgen Inc
NASDAQ:AMGN
36.9
44%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
269.7
187%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -235.5 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -515 N/A N/A
AU
CSL Ltd
ASX:CSL
27.3
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.9
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.6 N/A N/A
NL
argenx SE
XBRU:ARGX
44.2
28%
1.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average EV/EBITDA: 14.2
6.2
6%
1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 476.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
15.2
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.6
7%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.8
18%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560.8 N/A N/A
AU
CSL Ltd
ASX:CSL
16.9
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.4
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.2 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 501.1 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average EV/EBIT: 18.9
10.6
10%
1.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -199 177.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
28%
0.8
US
Amgen Inc
NASDAQ:AMGN
26.9
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.3
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -545.8 N/A N/A
AU
CSL Ltd
ASX:CSL
21.1
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.4
17%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 676.9 N/A N/A